Oncodaily·3 min read·hard
Jing Liang: Redefining Success in Long Term Cancer Drug Development
M
Mia Becker
✦AI Summary
Oncologists and entrepreneurs are debating the efficacy of different clinical trial designs for cancer drug development. The discussion centers on whether large crossover overall survival trials are superior to smaller objective response rate trials for regulatory approval.
Jing Liang , Entrepreneur, Drug hunter, shared on X :
healthbusiness
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in